Study drug for advanced lung cancer with a specific genetic change
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell lung cancer confirmed by a pathology test (biopsy/surgery).
- Your cancer has come back or spread (recurrent or metastatic).
- You’ve already had first treatment with platinum chemotherapy plus immunotherapy, either together or one after the other.
- Your tumor must have a matching genetic finding called NSD3 gain/amplification from an approved lab test (often NGS/ctDNA testing).
- You must be well enough for treatment (ECOG performance status 0–2) and have blood/liver/kidney/clotting tests within required limits.
- You must be able to swallow the study capsules and meet safety heart and infection rules (including no recent heart attacks/unstable chest pain and no uncontrolled serious infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.